What Is 3-Methylglutaconic aciduria type III

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 3-Methylglutaconic aciduria type III (MGA3) is a rare genetic disorder caused by mutations in the OPA3 gene, first described in 2007. It is characterized by optic atrophy, developmental delay, and elevated levels of 3-methylglutaconic acid in urine, with symptoms typically appearing before age 5.

Key Facts

MGA3 is caused by mutations in the OPA3 gene on chromosome 19q13.2-q13.3
It was first clinically described in 2007 in patients with optic atrophy and movement disorders
Symptoms usually manifest before age 5, including developmental delay and hypotonia
Over 30 cases have been reported worldwide as of 2023
Elevated urinary 3-methylglutaconic acid is a hallmark biomarker

Overview

3-Methylglutaconic aciduria type III (MGA3), also known as Costeff syndrome, is a rare autosomal recessive disorder primarily affecting neurological and visual function. It belongs to a group of metabolic conditions marked by increased urinary excretion of 3-methylglutaconic acid, a byproduct of abnormal leucine metabolism.

Unlike other forms of 3-methylglutaconic aciduria, type III is specifically linked to mutations in the OPA3 gene and is most prevalent in the Iraqi Jewish population due to a founder mutation. The condition typically presents in early childhood with progressive optic atrophy and motor dysfunction.

Optic atrophy: Degeneration of the optic nerve leads to progressive vision loss, often beginning in infancy and resulting in severe visual impairment by adolescence.
Mutations in OPA3: The disease-causing variants are located on chromosome 19q13.2-q13.3, with the most common being a splice-site mutation (c.131G>A) in exon 3.
Autosomal recessive inheritance: Both parents must be carriers for a child to inherit the condition, with a 25% recurrence risk in each pregnancy.
Founder effect: The high prevalence in the Iraqi Jewish community stems from a founder mutation dating back several generations, now seen in about 1 in 10,000 individuals in that group.
Metabolic marker: Elevated urinary 3-methylglutaconic acid is detectable via organic acid analysis, serving as a key diagnostic clue despite normal blood acylcarnitine profiles.

How It Works

The OPA3 gene encodes a mitochondrial protein involved in maintaining mitochondrial dynamics and energy production. Mutations disrupt mitochondrial function, leading to cellular stress and neurodegeneration, particularly in energy-demanding tissues like the optic nerve and basal ganglia.

OPA3 protein: This mitochondrial protein regulates inner membrane structure and fission; its dysfunction causes abnormal mitochondrial morphology and reduced ATP synthesis.
Leucine metabolism: Impaired mitochondrial function disrupts the breakdown of leucine, leading to accumulation of 3-methylglutaconic acid and 3-methylglutaric acid in urine.
Neurodegeneration: Basal ganglia and optic nerve degeneration result from chronic energy deficiency, causing choreoathetosis, spasticity, and dystonia observed in patients.
Onset age: Clinical signs typically emerge before age 5, with initial symptoms including delayed motor milestones and nystagmus.
Progression: Neurological symptoms worsen over time, with most patients requiring mobility aids by adolescence and severe visual impairment by age 10–15.
Diagnostic testing: Confirmation involves urine organic acid analysis, brain MRI showing basal ganglia abnormalities, and genetic testing for OPA3 mutations.

Comparison at a Glance

Below is a comparison of 3-methylglutaconic aciduria types I–IV and Costeff syndrome (type III):

Type	Gene	Key Features	Inheritance	Prevalence
Type I	AUH	3-methylglutaconic aciduria, speech delay	Autosomal recessive	Rare, <100 cases
Type II	TAZ (G4.5)	Barth syndrome, cardiomyopathy, neutropenia	X-linked	~1 in 200,000 males
Type III	OPA3	Optic atrophy, movement disorders, Iraqi Jewish origin	Autosomal recessive	~1 in 10,000 in Iraqi Jews
Type IV	Unknown	Heterogeneous, severe neonatal forms	Autosomal recessive	Extremely rare
Costeff syndrome	OPA3	Synonym for MGA3, same clinical features	Autosomal recessive	Same as Type III

This table highlights how MGA3 (Type III) is genetically and clinically distinct from other types, particularly due to its association with optic atrophy and a defined ethnic prevalence. While all types feature elevated 3-methylglutaconic acid, only type III and Costeff syndrome refer to the same condition.

Why It Matters

Understanding MGA3 has implications for genetic counseling, early diagnosis, and potential therapeutic development. Its well-defined genetic cause and population-specific prevalence make it a model for studying mitochondrial disorders.

Carrier screening: In high-risk populations like Iraqi Jews, carrier testing enables informed reproductive choices and prenatal diagnosis.
Early intervention: Prompt diagnosis allows for vision and motor support services to improve quality of life despite progressive symptoms.
Mitochondrial research: MGA3 provides insights into mitochondrial dynamics, aiding research on neurodegenerative diseases like Parkinson’s.
Gene therapy potential: As a monogenic disorder, MGA3 is a candidate for future gene-based treatments targeting OPA3 expression.
Global awareness: Only over 30 cases reported worldwide underscore the need for increased clinician awareness to reduce diagnostic delays.
Phenotypic spectrum: Expanding the known symptoms helps differentiate MGA3 from similar disorders, improving diagnostic accuracy.

While no cure exists, multidisciplinary care can manage symptoms and support affected individuals and families. Continued research into mitochondrial function may one day lead to targeted therapies for this rare but debilitating condition.